ASCO 2022 | How can MRD guide treatment of AML?

Christopher Hourigan • 4 Jun 2022

ASCO 2022

Acute Myeloid Leukemia Leukemia

Pre-Measure

Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, reflects on how measurable residual disease (MRD) testing can be used to guide the treatment and management of patients with acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Impact of conditioning intensity of allo-SCT for AML with molecular residual disease

Christopher Hourigan

Harmonizing MRD reporting criteria

Christopher Hourigan • 15 Jun 2018

Measuring MRD in AML: current landscape and future outlook

Christopher Hourigan • 15 Jun 2018

Heterogeneity in refractory AML

Christopher Hourigan

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

The future of AML therapy

Andreas Burchert

Treating pediatric patients with hematological malignancies

Claudia Rössig